BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series

1. Deng, Z, Morse, JH, Slager, SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737–744.
Google Scholar | Crossref | Medline | ISI2. International PPHC, Lane, KB, Machado, RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81–84.
Google Scholar | Crossref | Medline | ISI3. Swietlik, EM, Gräf, S, Morrell, NW. The role of genomics and genetics in pulmonary arterial hypertension. Glob Cardiol Sci Pract 2020; 2020: e202013.
Google Scholar | Medline4. Austin, ED, Phillips, JA, Cogan, JD, et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009; 10: 87.
Google Scholar | Crossref | Medline | ISI5. Girerd, B, Montani, D, Eyries, M, et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010; 11: 73.
Google Scholar | Crossref | Medline | ISI6. Pfarr, N, Szamalek-Hoegel, J, Fischer, C, et al. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 2011; 12: 99.
Google Scholar | Crossref | Medline | ISI7. Liu, D, Wu, WH, Mao, YM, et al. BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5: 511–518.
Google Scholar | Crossref | Medline | ISI8. Evans, JD, Girerd, B, Montani, D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4: 129–137.
Google Scholar | Crossref | Medline9. Morrell, NW, Aldred, MA, Chung, WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801899.
Google Scholar | Crossref | Medline10. Galiè, N, Channick, RN, Frantz, RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53:1801889.
Google Scholar | Crossref | Medline11. Boucly, A, Weatherald, J, Savale, L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50:1700889.
Google Scholar | Crossref | Medline12. Olivieri, C, Pagella, F, Semino, L, et al. Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. J Hum Genet 2007; 52: 820–829.
Google Scholar | Crossref | Medline13. Hemnes, AR, Zhao, M, West, J, et al. Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2016; 194: 464–475.
Google Scholar | Crossref | Medline | ISI14. Benza, RL, Gomberg-Maitland, M, Demarco, T, et al. Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1345–1354.
Google Scholar | Crossref | Medline | ISI15. Isobe, S, Kataoka, M, Aimi, Y, et al. Improved survival of patients with pulmonary arterial hypertension with BMPR2 mutations in the last decade. Am J Respir Crit Care Med 2016; 193: 1310–1314.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif